DeepMed Research

Sigma Tau I.f.r S.p.a.

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Phase 1

Terminated

Conditions: Skin Neoplasm
Pancreatic Neoplasm
Digestive System Neoplasm
Connective and Soft Tissue Neoplasm
Head and Neck Neoplasm
Respiratory Tract Neoplasm
Urogenital Neoplasm
Breast Neoplasm
Lymphoma, Non-Hodgkin

Interventions: Combination Product: 131I-Tenatumomab

First Posted Date: 2015-11-11

Last Posted Date: 2018-09-18

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 2

Registration Number: NCT02602067

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Institut Bergonnie, Bordeaux, France
🇫🇷
Icm Val D'Aurelle, Montpellier, France

and more 4 locations

A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria

Phase 2

Completed

Conditions: Malaria,Falciparum

Interventions: Drug: Eurartesim dispersible oral tablet
Drug: eurartesim film coated tablet

First Posted Date: 2013-11-25

Last Posted Date: 2016-11-08

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 300

Registration Number: NCT01992900

Locations: 🇧🇫
Centre Muraz, Bobo Dioulasso, Burkina Faso
🇹🇿
Bagamoyo Research center, Ifakara Heath Institute, Bagamoyo, Tanzania
🇧🇫
Centre National de Recherche et de Formation en Paludisme, Ouagadougou, Burkina Faso

and more 4 locations

ST1968 Intravenous (Weekly) in Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: ST1968

First Posted Date: 2012-12-12

Last Posted Date: 2012-12-12

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 62

Registration Number: NCT01748019

Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis; Efficacy, Safety and Tolerability Study

Phase 3

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Propionyl-L-Carnitine
Drug: Placebo

First Posted Date: 2012-03-30

Last Posted Date: 2016-11-06

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 150

Registration Number: NCT01567956

Locations: 🇭🇺
CRU Hungary Kft., Szikszó, Hungary
🇭🇺
Kaposi Mór Megyei Oktató Kórhaz Belgyógyászati Osztály, Kaposvár, Hungary
🇭🇺
Clinfan Kft. SMO, Szekszárd, Hungary

and more 55 locations

Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis

Phase 3

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Propionyl-L-Carnitine

First Posted Date: 2012-02-24

Last Posted Date: 2016-11-06

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 147

Registration Number: NCT01538251

Locations: 🇮🇱
Soroka University Medical Center, Beer Sheva, Israel
🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇱
Kaplan Medical Center, Rehovot, Israel

and more 55 locations

Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers

Phase 1

Completed

Conditions: Malaria, Falciparum

Interventions: Drug: Eurartesim

First Posted Date: 2010-10-18

Last Posted Date: 2010-10-18

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 37

Registration Number: NCT01222962

Locations: 🇦🇺
CMAX, a division of IDT Australia Limited, Adelaide, Australia

A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™

Phase 1

Completed

Conditions: Malaria, Falciparum

Interventions: Drug: Eurartesim

First Posted Date: 2010-10-18

Last Posted Date: 2010-10-18

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 80

Registration Number: NCT01222949

Locations: 🇦🇺
CMAX, a division of IDT Australia Limited, Adelaide, Australia
🇦🇺
Nucleus Network Limited, Melbourne, Australia

Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.

Phase 3

Completed

Conditions: Chronic Hepatitis C

Interventions: Biological: Thymosin alpha 1
Drug: Ribavirin
Biological: PEGinterferon alfa2a
Drug: Placebo

First Posted Date: 2010-08-10

Last Posted Date: 2010-08-10

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 552

Registration Number: NCT01178996

Locations: 🇮🇹
Università Cattolica del Sacro Cuore, Rome, Italy
🇮🇹
Dipartimento Medico Chirurgico delle Malattie dell'Apparato Digerente e della Nutrizione, Azienda Ospedaliera S Giovanni Battista, Turin, Italy
🇪🇸
Hospital del Mar, Barcelona, Spain

and more 6 locations

Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers

Phase 1

Completed

Conditions: Malaria, Falciparum

Interventions: Drug: Eurartesim™
Drug: Riamet®
Other: Placebo and finally Moxifloxacin

First Posted Date: 2010-04-15

Last Posted Date: 2011-06-17

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 287

Registration Number: NCT01103830

Locations: 🇫🇷
SGS aster s.a.s, Paris, France

A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine

Phase 2

Completed

Conditions: END STAGE RENAL DISEASE

Interventions: Biological: MF59 adjuvanted H1N1 influenza monovalent vaccine
Drug: Thymosin alpha 1

First Posted Date: 2009-12-15

Last Posted Date: 2012-03-29

Lead Sponsor: sigma-tau i.f.r. S.p.A.

Target Recruit Count: 120

Registration Number: NCT01031966

Locations: 🇮🇹
Second Division of Nephrology and Dialysis - Padua Hospital, Padua, Italy

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy